title: [Clinical features, diagnosis, treatment, and prognosis of 99 cases with primary intestinal lymphoma].
abstract: Objective:To investigate the clinical features, diagnosis, treatment and prognosis of primary intestinal lymphoma (PIL) .Methods:The characteristics, diagnosis, treatment methods, and follow-up outcomes of 99 PIL patients, diagnosed in Peking university cancer hospital between Nov.1,1995 and Nov. 30, 2013.Results:There were 65 males and 34 females with a median age of 50 years. The majority of clinical manifestation were non-specific gastrointestinal symptoms, 67.68% of cases presented abdominal pain, 26.26% with acute abdomen. The most common primary sites of ileum and ileocecus were identified in 21 cases, respectively. The positive rate of endoscopic was only 24.24%, and 69 cases were diagnosed by operation. 71 patients (71.72%) were stageⅠ-Ⅱand 28 patients (28.28%) were stage Ⅳ. Hodgkin's lymphoma was not found in all patients. Of the 99 cases, 77 were B-cell origin (77.78%) and 22 were T-cell origin. 55 cases (55.56%) were diagnosed with diffuse large B cell lymphoma (DLBCL) . 60 cases presented IPI score 0-1 point. The median overall survival (OS) was 100.0 months, and 5 year overall survival (5y-OS) was 53.5%. By multiple-factors analysis, T-cell origin lymphoma was significantly correlated with poor prognosis (P<0.05) . There was no difference of the median OS between the patients with operation and chemotherapy alone (79.0vs123.0 months,P=0.616) .Conclusion:PIL is commonly seen in males. Abdominal pain is the most common clinical manifestations and the most primary sites are ileum and ileocecus. The diagnosis value of the endoscopic is limited. DLBCL is the most common pathologic type of PIL. T-cell origin lymphoma is an independent prognostic factor for PIL. Surgery is still commonly used in the diagnosis and treatment of PIL, and the operation do not increase the risk of death of patients with PIL.
authors.affiliation: Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research（Ministry of Education）, Peking University School of Clinical Oncology, Beijing Cancer Hospital, Beijing Institute for Cancer Research, Beijing 100142, China.
authors.forename: L Y
authors.initials: LY
authors.lastname: Ping
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Song
authors.forename: W
authors.initials: W
authors.lastname: Zheng
authors.forename: X P
authors.initials: XP
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Xie
authors.forename: N J
authors.initials: NJ
authors.lastname: Lin
authors.forename: M F
authors.initials: MF
authors.lastname: Tu
authors.forename: Z T
authors.initials: ZT
authors.lastname: Ying
authors.forename: W P
authors.initials: WP
authors.lastname: Liu
authors.forename: C
authors.initials: C
authors.lastname: Zhang
authors.forename: L J
authors.initials: LJ
authors.lastname: Deng
authors.forename: J
authors.initials: J
authors.lastname: Zhu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms; D008223:Lymphoma; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies
keywords: Clinical features; Intestinal lymphoma; Prognosis; Treatment